Pinpoint SurgeryHow about something on Stansberry’s latest – “Pinpoint Surgery” stock?
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
The charts for ARAY look terrible so I nibbled this morn at $5.89 and it’s already down another penny. Assuming we picked the most likely stock to match the tease, there may be a few unhappy investors who plunked down $2500 for the tip. On the other hand, if we picked the right one, why don’t we see some positive action for a stock being touted by Stansberry?
This story in today’s WSJ about Proton-Beam therapy doesn’t concern the tease but is interesting nonetheless– here’s a link: http://www.wsj.com/articles/big-bets-on-proton-therapy-face-uncertain-future-1432667393?tesla=y
I haven’t a clue which company Paul is teasing and frankly don’t care. The one stock I am watching in this field is (MRIC) MRI Interventions, Inc. It’s just a penny stock at $1 plus but it has great potential.
I am still intrigued by the Stansberry teaser. I have listened to the recording a couple of times and he alludes to the fact that you can’t do a straight purchase and most people would play this wrong. So don’t know if he is just referring to options or a completely different play. So far we have ARAY, NVDQ and Elekta ((EKTAF :OTCPK) and Elekta publ AB (EKTAY :OTCPK). Are we convinced it is ARAY
It is DEFINITELY ARAY. Absolutely confirmed. Forget options – hardly any open interest and only for in the money strike.
Took a small 500 share position at $5.88.
nope
haha…
the patient stories he uses in the teaser video and the photos of the lung cancer improvement are straight off ARAY’s website postings of their patients…”a 75 year old man with brain cancer underwent blah, blah, blah previous surgeries”…this example he used is one of the stories on the ARAY website!
Can you provide a link to that please? Thanks
Er?…try yahoo… enter ticker ARAY…go to company website. It often works.
Well, duh, of course I did that. I’m not finding the same images on ARAY as found in Paul’s tease. That’s why I asked. It’s entirely possible I missed it, as there are quite a few testimonials, but seeing a match there for myself would convince me that it really is ARAY
http://www.accuray.com/sites/default/files/m-cln-023-1108_lsbrt-cs.pdf
I have it on v good authority (from someone who subscribes) its defo ARAY. But curiously it IS a straight buy….not options etc
For the inexperienced among us, of which I am one (but now that I am Irregular, those times they are a’changing), how would we go about making a straight buy?
This posting may be off-subject, but today I received an interesting health-care input from Microventures, a crowd-funded source of private offerings which are floated a long time (if ever) before becoming IPO’s. For a minimum investment of $5,000, Microventures offers an illiquid position in an outfit called “Agile MD” that now provides hospitals and doctors with up-to-date info on the latest medical care techniques. Agile MD claims to have some serious health-care “partners” such as Univ. of Chicago, Stanford, etc. I wonder if Dr.KSS or other MDs could view the service as being useful? Here’s a link:
https://microventures.com/offerings/agilemd
I would be interested in any comments on this from other fellow-gummies?
Great reading your great guesswork and evidence. Cellectar BioSciences (CLRB) was not mentioned? Any promise here?
Or what about the advert now at top of this page?
Leksell Gamma Knife Icon
Have you seen Icon? The latest in cranial radiosurgery
Clearly Google ads have made the association. Watch out Travis, Google’s after your job ! 🙂 http://www.careforthebrain.com/?gclid=CJmwxP3D6cUCFVMatAod3G4A9w
How does one submit ideas for deconstruction to The Thinkolater and crew? Here’s one that I received through ETF.db:
Apple has some important news concerning your credit card…
Dear Investor,
$18 million PER day!
That’s how much money American Express, Capital One, Chase, Discover and all the other credit card companies could soon be losing thanks to an unprecedented shift in the way Americans use their credit cards. Likely, you’ve already heard a lot about this monumental development… Yet I can almost guarantee you haven’t heard the full story – the story that will lead you straight to an investment in the little-known company that’s at the epicenter of all this excitement. See, recently Apple CEO Tim Cook unveiled Apple Pay – the highly anticipated system that lets you use your phone in place of your credit card. Already, more than 750 banks are allowing their customers to use Apple’s revolutionary system. They’re happily giving up as much as $18 million per day – that’s an astonishing $6.57 billion per year! – just to be a part of Apple’s payment revolution. And now, from Whole Foods to Panera to Target, Office Depot, and everything in between, more than 220,000 merchants all across the country are falling all over themselves to partner with Apple. But here’s the thing…
Investing in Apple isn’t the best way to take advantage of this massive opportunity. That’s because Apple isn’t even responsible for developing the technology that makes mobile payments possible… And along with Google, Microsoft, Samsung, Nokia, Motorola, and just about every other major phone manufacturer… They’re now paying the company that invented this technology hundreds of millions of dollars each year to get it inside their phones. So the million dollar question is who is the company supplying this amazing component to these Titans of Technology? Well, The Motley Fool knows because we’ve been digging into this exciting story for months. Which is why I hope you take just a few minutes to access this exclusive research our team of analysts put together to help put you in the position to profit for years to come from this explosive chain of events. Check out this exclusive report right now for the full story, and to learn about the company behind this cutting-edge technology… before the masses jump on board and drive its stock price straight through the roof!
Act now!
To your wealth!
Signature
Dan Ferrari
Consumer Research Analyst,
The Motley Fool
Gary Fox: Send to Info @ stockgumshoe.com
Thanks. I’m on it.
BTW you should cummon down to the SG irregulars for a whole $49 pa….whole lotta shaking going on down there. Best money youll EVER spend. See ya on the KSS thread
——————————–
Sorry, we were unable to deliver your message to the following address.
:
Remote host said:
550-5.1.1 The email account that you tried to reach does not exist.
——————————————-
Opps….try Travis @stockgumshoe.com or Lynn @stockgumshoe.com for the office. They defo work. Sorry.
Found this: ILoveStockSpam@gmail.com
on the website somewhere…..
I think thats another route. the list is near endless at gumshoe ! Enjoy
You got it! You can send teasers to ILoveStockSpam@gmail.com, Travis@stockgumshoe.com, Lynn@stockgumshoe.com, Admin@stockgumshoe.com, or use the “Contact” button at the very top of the page. Gary, thanks for your interest, and Benny, thanks for pointing him in the right direction!
I believe the stock they are touting is NXPI, they are the leader in NFC (near Field Communications). It is in the new Apple iPhones (6, 6+,6c ), also in the new Samsung phone.
NXPI also produces the security chips in credit cards, and the NFC chips for VISA and MC sales terminals. Andy Obermueller of Game Changing Tech put me onto this over a year ago. The stock is now around $110 and still has plenty of upside, and yes a better buy than Apple (although I own both + SWKS, INVN & AMBA). NXPI is a tech Titan, and its focus is solely on sectors where it can be the dominant player. It is in the process of acquiring Freescale. Read the recent article of the 4 supplier stocks benefitting from Apple’s new iPhone by Andy Obermueller. Don G.
Yes, Obermueller and the Motley Fool and David Eifrig and others have all touted NXPI in the last couple years.
Up 175% on nxpi . Motley Rule Breaker.
370% on AMBA
John P: What are you saying….if you throw enough shite at the wall, some will stick?
how can you guys be so sure it is ARAY when they are a radiation company not a surgical company, as mentioned in the tease?
Larry: Id cut and paste you the text….but Id get sued. Perhaps ask Standsberry that question after some DD.
ARAY got an FDA approval for Cyberknife in 2001. It could not show a business success for a long time. What is the guarantee, that it will be succeded later on?
Shanghai: I see no money here. Theyre not selling pills across the counter and theres no repeat prescription. If your country is like the UK, they will have two of these machines at specialist centres….you go to it by appointment….a whole two !
The tease mentions an award won in 2010, from ARAY site:
SUNNYVALE, Calif., November 29, 2010 – Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company’s CyberKnife® VSI System received the 2010 Minnie for Best New Radiology Device from AuntMinnie.com, the largest and most comprehensive community internet site for radiologists and related professionals in the medical imaging industry. Accuray will be presented with the award at the 2010 Radiological Society of North America (RSNA) annual meeting taking place in Chicago, Ill. from November 28 – December 3, 2010.
Am I sure glad I came here instead of paying $2,500 up front! I like the idea of Professional Speculator and of minimally-invasive cancer surgery, but that doesn’t necessarily make Accuray is a good company to invest in. According to TheStreet, Accuray has “disappointing return on equity, weak operating cash flow, generally disappointing historical performance, and high debt management risk.”
Here are two news segments on CyberKnife I found:
http://video.foxnews.com/search?q=cyberknife
CyberKnife uses what’s called “external beam therapy,” so if that interests you, can search the Internet to learn more about that topic.
Joseph, since you’re up $2,500 you may want to consider joining the Irregulars and have access to the best biotechnology forum on the internet. Best2Ya!-Benjamin
i THINK PINPOINT SURGERY IS A FIGURE OF SPEECH DESCRIBING PINPOINT ACCURACY, I.E. IT IS A TECHNOLOGY THAT DISOLVES ONLY THE DISEASED CELLS. IT CANNOT BE INVASIVE, BECAUSE THE PATIENTS CAN WALK AWAY FROM THE “OPERATION” TABLE. IT MUST BE A DRUG.
No it’s not a drug at all – it is a form of laser/radiation type treatment, similar to what they use to treat brain tumors without opening the skull, etc…
If External Beam Therapy, then not a drug but targeted radiation therapy:
http://www.radiologyinfo.org/en/info.cfm?pg=ebt
How this compares with alternatives, and whether there is less toxicity (fatigue, nausea, skin damage) than other radiotherapies, I do not know.
I reviewed the audio/video sales pitch for the Stansbury/Pamphill ‘pinpoint surgery’ tout. Listed below are the salient points mentioned in the video for perusal. I have not yet compared these tidbits with the ARAY Website or other possible companies listed above.
A small biotech company.
Tiny company.
Relevant to cancer surgery.
‘Pin Point Surgery’, it could replace conventional cancer treatment surgery.
No knife, no cuts.
Works on dozens of different parts of the body. Mentions brain cancer, lung cancer, head and neck,kidney, pancreas, prostate, spine, facial paralysis.
Eliminates overnight stays in hospital. Patients back to work same day or next day.
Success rate 98% treating one aggressive type of tumor.
A device.
No drugs, full-body radiation or chemotherapy.
The disease tissue vanished.
A 45 minute procedure.
‘Revolutionary’ according to a Harvard Medical Teaching Hospital.
One of America’s oldest hospitals to receive device.
The Government’s National Institutes of Health (NIH) posted a Stanford University School of Medicine study of 51 patients suffering from spinal tumors…who all underwent ‘pinpoint surgery’. Success rate 94%.
Already received FDA approval for its approach.
Study published by the University of Miami says “it’s ‘feasible and safe’ and ‘achieves excellent rates of success in killing diseased tissue… with sub-millimeter pinpoint accuracy.”
Dozens of patient reports.
Patient listened to music during the procedure so probably not sedated.
Could treat 90% of a $100 billion market.
Trading for less than $10.
The company signed a contract with one of the biggest hospital alliances in America which provides healthcare solutions to nearly 60% of US hospitals.
Popular on bulletin boards where patients discuss their options.
What I’m confused about here is that several people have confirmed that it is indeed ARAY – one said he has it on authority from a subscriber that it is ARAY – yet many of you are still trying to work it out, posting more clues, etc. Why?
I for one am not comfortable with ARAY so the more digging the better.
Hello everyone – I’m new here – but appreciate all the digging. So much so that I joined the Irregulars and am enjoying reading all the research. I listened to the 25 minute ARAY presentation from the Jefferies conference yesterday and everything they say (the presentation is available as a PDF on their web site) seems to confirm all the research you have all done. I am just befuddled that this company is being positioned to folks as a speculation with great growth potential. I just can’t seem to figure out what the basis of the speculation is. The company itself says that Year over Year Growth for EBITDA is forecast to be in the range of “flat to 20%”. Is there some event coming up where ARAY will reveal a large increase in sales? A new contract? A breakthrough in their software? Is the stock under-valued? I just don’t see any data in the public eye that could cause anyone to believe that ARAY could grow hundreds of percent in the next few years. Perhaps the speculation is meant to be long term? For now, I’m stumped, but find this interesting. (And I continue to learn lots). So – thanks for everyone’s input and digging.
Welcome Jeffro1! If you’re into biotechnology check out the current thread: http://www.stockgumshoe.com/2015/05/a-biotech-long-idea-brought-to-you-on-bended-knee/ You’ll learn a ton and enjoy all the tools available to you as an Irregular. Best2Ya-Ben
I feel the same way, just not sold on ARAY. It’s a bit surprising and I can’t help but wonder if we’re right on this call, despite the information we’ve found that certainly seems to jive up. I don’t see myself buying into ARAY at this point, but maybe Mampilly will get the last laugh.